Chemical Company of Malaysia Berhad Annual Report 2019

| OTHER DISCLOSURES | UTILISATION OF PROCEED FROM CORPORATE PROPOSALS (If any) On 20 March 2019, the Company announced the completion of the proposed disposal of its Nilai land with total proceeds of RM21.5 million which had been fully utilises towards repayment of bank borrowings. AUDIT AND NON-AUDIT FEES FOR SERVICES RENDERED TO THE LISTED ISSUER OR ITS SUBSIDIARIES FOR THE FINANCIAL YEAR During the year ended 31 December 2019, the following amount have been paid or payable to the auditors of the Company and Group for work performed: Audit Work (RM) Non-Audit Work (RM) Company Level 77,000 30,000 Group Level 344,000 30,000 MATERIAL CONTRACTS INVOLVING INTERESTS OF DIRECTORS, CHIEF EXECUTIVE OFFICER WHO IS NOT A DIRECTOR OR MAJOR SHAREHOLDER Save as disclosed below, there was no other material contract involving the interests of directors, chief executive officer who is not a director or major shareholder interest, either subsisting at the end of the financial year ended 31 December 2019 or if not, entered into since the end of the previous financial year, other than contracts entered into in the ordinary course of business: a) CCM Chemicals Sdn Bhd (“CCMC”), a wholly owned subsidiary of the Company had, on 29 November 2019, awarded a contract to Sime Darby Energy Solutions Sdn Bhd, a wholly subsidiary of Sime Darby Berhad to engineer, procure, construct and commission one unit of Co-Generation (“COGEN”) plant at CCMC’s Pasir Gudang chlor-alkali plant in Johor at a contract price of RM27.9 million. b) Commodity Murabahah Term Financing-i Commodity Facility (the “Facility”) of USD25.0 million (or approximately equivalent to RM100 million) entered into between CCM and Sumitomo Mitsui Banking Corporation Malaysia Berhad (“SMBC”) on 18 April 2018 for the purpose of facilitating the overall cashflow planning and loan restructuring exercise of the Company. c) Share Sale Agreement dated 13 April 2018 between Chemical Company of Malaysia Berhad (“CCM”) and Duopharma Biotech Berhad (“Duopharma”) for disposal by CCM of 806,405 common share in Pangen Biotech Inc (‘Pangen”), representing approximately 8.39% equity interest in Pangen, to Duopharma for a cash consideration of RM59,156,546.56. The disposal was completed on 29 June 2018. d) Information Technology Services Agreement dated 11 April 2018 between CCM and Duopharma for the provision on information technology services by CCM to Duopharma for a fixed term commencing from 1 January 2018 to 1 January 2022. Duopharma had given notice to terminate the information Technology Services Agreement effective on 30 June 2020 via a notice of termination dated 28 June 2019. e) Sub-tenancy Agreement dated 10 April 2018 between CCM and Duopharma whereupon CCM has granted to Duopharma the sub-tenancy of Level 13 and Level 14 of Menara PNB, 201-A, Jalan Tun Razak, 50400 Kuala Lumpur for the sum of RM7,700.00 per month for a fixed term commencing on 1 January 2018 and expiring on 14 February 2020. Duopharma had terminated the sub-tenancy effective on 31 October via a notice of termination dated 30 July 2018. 108 CHEMICAL COMPANY OF MALAYSIA BERHAD